Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited announced a change in the director’s interest, with Director James Garner acquiring an additional 2,500,000 fully paid ordinary shares, increasing his holdings to 52,500,000 shares. This acquisition, conducted through an on-market purchase valued at $24,960, reflects a strategic move to strengthen the director’s stake in the company, potentially signaling confidence in the company’s future prospects and stability in the biotechnology market.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is involved in the research and production of innovative treatments, aiming to address unmet medical needs in the healthcare sector.
Average Trading Volume: 2,513,005
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
See more insights into PER stock on TipRanks’ Stock Analysis page.